Buy NAD+ 500mg

Nicotinamide adenine dinucleotide (NAD+) is a fundamental coenzyme present in every living cell, serving as the primary electron carrier in the mitochondrial electron transport chain (ETC) and as the obligate substrate for two critical classes of longevity-associated enzymes: sirtuins (SIRT1–7) and poly(ADP-ribose) polymerases (PARPs). In oxidative phosphorylation, NAD+ accepts electrons at Complex I (NADH dehydrogenase) and Complex III, cycling between its oxidized (NAD+) and reduced (NADH) forms to power ATP synthesis. When cellular NAD+ levels fall — as they consistently do with aging, typically declining 40–60% between young adulthood and old age — mitochondrial efficiency collapses, metabolic flexibility is lost, and cells shift toward glycolytic energy production even under aerobic conditions, a hallmark of aged tissue metabolism. Sirtuins are a family of NAD+-dependent deacylases that regulate an extraordinary breadth of cellular processes including DNA damage repair, inflammation, mitochondrial biogenesis, and stress resistance. SIRT1 deacetylates PGC-1α to promote mitochondrial biogenesis and FOXO transcription factors to upregulate antioxidant defenses. SIRT3 maintains the acetylation status of ETC components, directly influencing Complex I activity and ROS production. SIRT6 regulates telomere maintenance and DNA double-strand break repair. All of these functions are NAD+-dependent: when NAD+ is depleted, sirtuin activity plummets regardless of the abundance of the sirtuin proteins themselves, creating a biochemical bottleneck that accelerates the aging phenotype across virtually every tissue type. PARPs, particularly PARP1, consume enormous quantities of NAD+ during DNA damage responses. As organisms age, cumulative genomic damage increases, driving persistent PARP1 hyperactivation that further depletes the NAD+ pool in a vicious positive-feedback cycle. This PARP-sirtuin competition for NAD+ was elegantly demonstrated by David Sinclair's group at Harvard, who showed that pharmacological PARP inhibition partially rescued sirtuin function in aged mice — an effect equivalent to that seen with NAD+ precursor supplementation. Restoring NAD+ levels therefore simultaneously relieves this competitive drain and provides the substrate necessary for sirtuin reactivation. Intravenous or subcutaneous NAD+ administration bypasses the gastrointestinal conversion steps required by oral precursors such as NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside). Both NMN and NR must be phosphorylated and adenylated intracellularly before joining the active NAD+ pool; direct NAD+ infusion, by contrast, provides the complete coenzyme immediately available for enzymatic reactions. Plasma NAD+ levels after IV administration rise far more rapidly and to higher concentrations than those achievable with oral precursors, making parenteral NAD+ the preferred route when rapid repletion is clinically indicated — as in post-chemotherapy recovery, neurological conditions, or acute metabolic rehabilitation.

Injectable NAD+ for research or clinical use should be pharmaceutical-grade, supplied as a lyophilized powder with a certificate of analysis confirming identity by HPLC and mass spectrometry, bacterial endotoxin testing (LAL method, <0.5 EU/mg), and sterility testing. NAD+ is relatively labile in solution — particularly sensitive to light and elevated pH — so products supplied as ready-to-inject liquid solutions require careful attention to packaging and storage claims. Lyophilized powder reconstituted in sterile physiological saline or 5% dextrose immediately before use is the most reliable approach. Dosing for IV protocols in published human studies has ranged from 250 mg to 1,000 mg per session, administered over 2–4 hours depending on the dose and individual tolerance. Starting at 250–500 mg with a slow infusion rate (4 hours) and titrating upward over subsequent sessions allows the user to characterize personal tolerability before advancing to higher doses. SubQ administration of smaller doses (25–100 mg) is increasingly reported in self-experimentation communities and may offer a convenient alternative to IV for maintenance dosing after initial repletion. When comparing NAD+ directly to oral NMN or NR supplements, consider the use case: oral NMN at 500–1,000 mg/day provides a convenient, noninvasive route with meaningful plasma NAD+ elevation documented in clinical trials and is appropriate for long-term maintenance. Parenteral NAD+ is better suited to acute therapeutic goals — rapid repletion in the context of aging reversal protocols, recovery from illness, or situations where gut absorption is compromised. A rational strategy combines a short IV loading course followed by oral NMN maintenance.

The NMN vs. NR vs. NAD+ debate is fundamentally a question of pharmacokinetics and bioavailability. NR enters cells via nucleoside transporters and is phosphorylated to NMN by NRK1/2, then adenylated to NAD+. NMN has a less clearly defined direct transport mechanism — CD73 can dephosphorylate it to NR first — though SLCO4C1 has been proposed as a direct NMN transporter in some tissues. Direct NAD+ circumvents all of these conversion steps, delivering the complete coenzyme immediately. The tradeoff is cost and administration route: parenteral NAD+ requires sterile preparation and injection, while NMN and NR are convenient oral capsules. Within Apollo's longevity lineup, NAD+ pairs most naturally with Epithalon and GHK-CU. Epithalon targets the telomere-telomerase axis and circadian restoration; GHK-CU resets the gene expression landscape across collagen maintenance and antioxidant defense; NAD+ restores the mitochondrial energy and DNA repair infrastructure that both of those upstream processes depend on. This three-way combination covers mitochondrial dysfunction, epigenetic drift, and telomere attrition — the three most mechanistically distinct and actionable hallmarks of aging — through entirely complementary pathways, making the combination more powerful than any single compound in isolation.